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Surveillance for Vancomycin-Resistant Enterococci:
Type, Rates, Costs, and Implications
Brooke N. Shadel, PhD, MPH; Laura A. Puzniak, PhD, MPH; Kathleen N. Gillespie, PhD; Steven J. Lawrence, MD;
Marin Kollef, MD; Linda M. Mundy, MD
objective. To evaluate 2 active surveillance strategies for detection of enteric vancomycin-resistant enterococci (VRE) in an intensive
care unit (ICU).
design. Thirty-month prospective observational study.
setting. ICU at a university-affiliated referral center.
patients. All patients with an ICU stay of 24 hours or more were eligible for the study.
intervention. Clinical active surveillance (CAS), involving culture of a rectal swab specimen for detection of VRE, was performed
on admission, weekly while the patient was in the ICU, and at discharge. Laboratory-based active surveillance (LAS), involving culture of
a stool specimen for detection of VRE, was performed on stool samples submitted for Clostridium difficile toxin detection.
results. Enteric colonization with VRE was detected in 309 (17%) of 1,872 patients. The CAS method initially detected 280 (91%) of
the 309 patients colonized with VRE, compared with 25 patients (8%) detected by LAS; colonization in 4 patients (1%) was initially detected
by analysis of other clinical specimens. Most patients with colonization (76%) would have gone undetected by LAS alone, whereas use of
the CAS method exclusively would have missed only 3 patients (1%) who were colonized. CAS cost $1,913 per month, or $57,395 for the
30-month study period. Cost savings of CAS from preventing cases of VRE colonization and bacteremia were estimated to range from
$56,258 to $303,334 per month.
conclusions. A patient-based CAS strategy for detection of enteric colonization with VRE was superior to LAS. In this high-risk setting,
CAS appeared to be the most efficient and cost-effective surveillance method. The modest costs of CAS were offset by the averted costs
associated with the prevention of VRE colonization and bacteremia.
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Infections caused by multidrug-resistant organisms are as-
sociated with increased morbidity and mortality,1-11 prolonged
hospital stays, and excess costs.9,12-14 Adverse effects of infec-
tion with multidrug-resistant organisms lead not only to
higher healthcare costs but also to higher societal costs in
terms of decreased productivity and quality of life for patients
and their families.15 Because enteric colonization with van-
comycin-resistant enterococci (VRE) is an important risk fac-
tor for VRE infection, prevention of colonization through
identification of others who are colonized, followed by im-
plementation of measures to control the spread of VRE after
their identification, seem imperative.9,16-19
Existing guidelines recommend that healthcare facilities de-
velop and implement a plan to prevent and control the spread
of VRE.9,20 However, definitive recommendations regarding
methods of surveillance have not been determined. Although
the costs of surveillance for enteric VRE have only begun to
be described,5,21,22 the attributable costs to the healthcare sys-
tem associated with VRE bacteremia alone may justify sur-
veillance and control programs.5,7,8,13,23,24 Identification of
VRE-colonized patients and implementation of contact iso-
lation have been shown to be cost-effective and may reduce
VRE-related morbidity and mortality in populations at high-
risk for VRE acquisition.5,6,23,25-28
A variety of active and passive surveillance methods have
been used for detection of enteric VRE.5,15,22,24,29-34 A few stud-
ies have compared active surveillance methods but were un-
able to conclude which method was superior.31,32,34 The ob-
jectives of this study were to compare the performance of 2
active surveillance strategies for detection of enteric VRE and
to describe the associated costs and implications of these
strategies.
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table 1. Demographic and Clinical Characteristics of 1,872 Intensive Care Unit
Patients by Vancomycin-Resistant Enterococci (VRE) Colonization Status
Variable








White race 109 (60.0) 73 (57.5) 867 (55.5)
Male sex 74 (40.7) 59 (46.5) 761 (48.7)
Bacteremia, by causal pathogen
MRSA 14 (7.7) 14 (11.0) 126 (8.1)
Pseudomonas aeruginosa 3 (1.6) 4 (3.1) 26 (1.7)
Clostridium difficile 8 (4.4) 15 (11.8) 70 (4.5)
Mortality 79 (43.4) 47 (37.0) 396 (25.3)
Continuous
Age, y 62.3  17.6 62.5  15.9 58.9  17.9
Duration of MICU stay, db 7.5  8.7 16.9  18.5 5.5  7.6
Duration of hospitalization, db 23.2  31.2 33.7  27.8 14.7  19.8
APACHE II scorec 24.4  7.5 23.9  6.3 21.1  8.2
note. Data are no. (%) of patients or mean . See Methods for definitions ofvalue SD
colonization status. APACHE, Acute Physiology and Chronic Health Evaluation; MICU, medical
intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus.
a Four patients with VRE initially detected in culture of a nonsurveillance clinical isolate (ie,
culture of sterile body fluid, performed as a component of routine clinical care) were categorized
as having VRE identified through CAS.
b Defined as the time of admission through the time of discharge.
c From Knaus et al.41
methods
Setting and Patients
Eligible participants were all patients admitted from July 1,
1997, through December 31, 1999, to the 19-bed medical
intensive care unit (ICU) at Barnes-Jewish Hospital (BJH), a
1,287-bed tertiary care facility in St. Louis, Missouri. Data
on patients residing in the ICU for 24 hours or more were
included; data from multiple admissions were combined if
subsequent admissions occurred 30 days or less after the ini-
tial admission. Data from only the first admission were in-
cluded in the analysis if subsequent admissions occurred more
than 30 days after the initial admission. Patients were ex-
cluded if microbiological data were incomplete or the pa-
tients’ medical records could not be reviewed. The research
review committees at Saint Louis University (St. Louis) and
Washington University Medical Center (St. Louis) approved
this study.
Study Design and Definitions
Clinical active surveillance (CAS) for VRE was defined as
prospective screening using rectal swab specimens. The CAS
method was performed by clinical staff who procured speci-
mens for detection of enteric VRE from all ICU patients at
ICU admission, ICU discharge, and every 7 days if the ICU
stay was 7 days or longer. Laboratory-based active surveillance
(LAS) was defined as screening of clinical stool specimens for
VRE that were originally collected for Clostridium difficile
screening in accordance with hospital-wide policy established
on October 1, 1996.35 Patients with enteric VRE initially de-
tected in culture of a nonsurveillance clinical isolate (ie, culture
of sterile body fluid, performed as a component of routine
clinical care) were categorized as having VRE identified through
clinical specimens. Stool samples submitted by 12 patients for
C. difficile testing at the time of admission were classified as
CAS specimens. Patients with a stool specimen positive for C.
difficile toxin by cytotoxicity assay (Bartels) were categorized
as having C. difficile–associated diarrhea or colitis.
Patients with VRE detected by surveillance or clinical cul-
ture before or on admission to the ICU were classified as
having a prevalent case of VRE colonization. Patients with
enteric VRE acquired during ICU stay were characterized as
having an incident case of VRE colonization. Patients with
negative culture results from the time of admission through
the time of discharge were classified as being VRE negative.
The incidence density was calculated by dividing the number
of patients with an incident case of VRE colonization by the
number of inpatient-days in the ICU from either admission
until discharge (for patients without VRE colonization) or
from admission until the date of initial VRE detection (for
patients with VRE colonization).
Data Collection
During the study period, differential infection control strat-
egies were used for the scheduled rotation of antimicrobial
therapy and gown use, as described elsewhere.6,29 Cost data
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table 2. Costs Attributable to Clinical Active Surveillance (CAS) and Laboratory-Based Active











Nursing time (6 min per specimen) 2.70 8,705 1,517
Laboratory technologists’ time
9.6 min per negative culture result 2.78 7,542 1,187
15.9 min per positive culture result 4.97 2,540 671
Supply costs
Fixed negative surveillance test results 5.00 13,565 2,135
Fixed positive specimens 13.00 6,643 1,755
Processing costs
Initial laboratory cost per culture 1.20 3,869 674
Extra laboratory cost per positive culture result 1.97 1,007 266
Stool collection cups 0.07 NA 40
Swabs 0.28 903 NA
Hand hygienec 0.10 322 56
Gloves 0.07 226 39
Total cost per negative test result 12.13 … …
Total cost per positive test result 24.29 … …
Total cost of surveillance program … 45,321 8,341
Total cost of surveillance program in 2003 US dollars … 57,395 10,563
Monthly cost of surveillance program in 2003 US dollars … 1,913 352
Cost of surveillance program per patient in 2003 US dollarsd … 30.66 5.64
note. Costs are in 1997 US dollars, unless otherwise indicated. Costs in columns indicating totals have been
rounded. See Methods for definitions of CAS and LAS. NA, not applicable.
a A total of 2,713 negative test results and 551 positive test results.
b A total of 427 negative test results and 135 positive test results.
c Comprised the cost of alcohol foam and of soap and water with paper towels.
d Of 1,872 patients who met the study criteria, 759 were excluded because they had a stay of less than 24 hours
(748 patients) or had incomplete data (11 patients).
were harvested through the hospital laboratory information
system and the hospital informatics system.36
Cost Data
Program costs were obtained from 2 clinical databases and
1 cost administrative database. Costs, rather than charges,
were used because they represent the cost to the institution
undertaking a surveillance program. The cost data were har-
vested in 1997 and 1998 US dollars, reflecting the value of
the US dollar during the study period. The total costs of the
surveillance program were converted to 2003 US dollars using
the medical care component of the Consumer Price Index37
and are reported in the text in 2003 US dollars.
Labor, supply, and processing costs were reported for cul-
tures with positive results and cultures with negative results.
Labor costs included estimated staff expenditures. The cost
of the technologists’ time to receive, process, finalize, and
report the specimen was converted to dollars, using the mean
salary of a technologist at BJH in 1997, and added into the
final cost of the test. The amount of time spent for specimen
procurement by healthcare personnel was estimated to be 6
minutes per specimen. The mean hourly wage, excluding
fringe benefits, calculated for the staff collecting the speci-
mens was $27.00 in 1998 (study midpoint). The combined
costs for the performance of hand hygiene before and after
each patient encounter was estimated to be $0.10. The supply
costs included the fixed costs per test that did not vary with
the volume of testing.
Estimated Cost Savings
Detection of VRE should lead to fewer cases of colonization
and bacteremia and, therefore, lower costs of hospitalization.
To estimate the cost savings associated with averted cases,
transmission of VRE was varied between a predictive rate of
0.5 and 2 times the rate.38 The proportion of VRE-colonized
patients who became bacteremic in this study was 7.8%,
slightly lower than the rates of up to 13.4% reported in 3
distinct oncology populations.16,18,39 These differential rates
were used to estimate the number of at-risk bacteremic pa-
tients. The excess cost of each case of VRE colonization was
estimated using the values $3,06525 and $9,97040 (both in 2003
dollars) obtained from the literature. The excess healthcare
cost of each case of VRE bacteremia was estimated as $17,1438
and $36,380.13
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table 3. Clinical and Epidemiological Characteristics of Vancomycin-Resistant Enterococci (VRE)








Overall 3,786 2,684 575 1,734
Negative results 3,140 2,173 427 1,552
Positive results 646 511 148 182
Patients with VRE detected, no.
Overall 309 306 75 182
Detected at admission 182 182 38 182
Detected during hospital stay 127 124 37
Patients with no VRE detected, no.
During hospital stay 0 3 234 127
At admission 0 0 144 0
Patients with bacteremia but no VRE detected, no. 0 0 9 10
Transmission dynamic of undetected VREa
0.50 190.5 186 160.5 Referent
2.00 381 372 321 Referent
Likelihood of colonized patient becoming
bacteremica
0% 0 0 0 Referent
7.8% 20 19.5 17 Referent
13% 33 32.22 28 Referent
note. See Methods for definitions of clinical active surveillance (CAS) and laboratory-based active surveillance
(LAS).
a Number of patients colonized as a result of contact with a colonized patient. The value 7.8% is from Puzniak
et al.29; the value 13% is from Leber et al.,22 Mayhall et al.,23 and Hachem et al.24
Statistical Analysis
SPSS statistical software, version 11.0 (SPSS), was used for
all analyses. Descriptive analyses were performed, including
analyses of frequencies, mean values, and median values.
results
Patients
Of 2,631 admitted patients, 1,872 (71%) met the study cri-
teria; 748 patients (28%) with an ICU stay of less than 24
hours and 11 patients with incomplete or missing medical
records were excluded. Demographic and clinical character-
istics by VRE colonization status are reported in Table 1. The
mean length of ICU stay (SD) for the study cohort was
days, although a prolonged mean duration of ICU6.7 9.3
stay (SD) of days was observed for patients16.9 18.5
with incident enteric colonization with VRE. Few patients
(less than 10%) had coexisting methicillin-resistant Staphy-
lococcus aureus or Pseudomonas aeruginosa bacteremia. Over-
all crude mortality was 28% and was higher among patients
with enteric VRE.
Surveillance
A total of 3,224 rectal swab specimens and 562 stool speci-
mens were tested for VRE (Table 2). Patients who acquired
VRE had approximately 1 more active screen culture per-
formed (mean [SD] of CAS cultures and0.97 1.87
CAS swab samples per patient), compared with2.8 1.5
patients colonized with enteric VRE on admission (mean
[SD] of CAS cultures and CAS0.38 0.91 1.8 0.85
swab specimens per patient) and patients who remained neg-
ative for VRE through discharge (mean [SD] of 0.24
CAS cultures and CAS swab specimens per0.74 1.6 1.0
patient). In total, 309 patients (17%) were VRE colonized;
182 (59%) had VRE detected on admission (prevalent cases),
and 127 patients (41%) acquired VRE (incident cases) (Table
3).
Among VRE-colonized patients, VRE was initially detected
in 280 (91%) by CAS, in 25 (8%) by LAS, and in 4 (1%) by
analysis of clinical specimens. The incidence density of VRE
was 12.7 cases of acquired VRE per 1,000 ICU patient-days.
VRE in most (100 [79%]) of the 127 patients who acquired
VRE was detected by CAS. The LAS method alone would
have missed 234 cases of enteric colonization with VRE
(76%), 144 (62%) of which were prevalent cases and 90 (38%)
of which were incident cases. Three cases (1%) would not
have been identified without LAS. A consistent pattern of
VRE surveillance occurred (Figure). Approximately 20 LAS
screening cultures per month were completed, compared with
116 CAS screening cultures per month. Screening on ad-
1072 infection control and hospital epidemiology october 2006, vol. 27, no. 10
figure. Comparison of clinical active surveillance (CAS) with laboratory-based active surveillance (LAS), by number of cultures
performed and number of cultures with positive results, at Barnes-Jewish Hospital during a 30-month period. See Methods for definitions
of CAS and LAS.
table 4. Characteristics of Surveillance Performed for 5 Patients for Whom Results of Cultures for Detection of Vancomycin-Resistant





Admission No. 2 No. 3 No. 4 No. 5 No. 6 No. 7 No. 8 Discharge
Patient 1
Type LAS LAS CAS LAS LAS LAS LAS LAS CAS
Test result Positive Negative Negative Negative Negative Positive Positive Positive Positive
Datea 12/19 12/22 12/23 12/24 12/25 1/2 1/3 1/4 1/16
Patient 2
Type CAS CAS CAS LAS CAS CAS … … CAS
Result Negative Negative Positive Negative Positive Negative … … Negative
Datea 1/11 1/15 2/2 2/6 2/7 2/25 … … 2/26
Patient 3
Type CAS LAS CAS LAS LAS CAS CAS … CAS
Result Negative Negative Negative Negative Positive Positive Negative … Negative
Datea 10/21 10/2 11/8 11/20 11/21 11/23 11/24 … 11/29
Patient 4
Type CAS CAS LAS CAS CAS CAS LAS … CAS
Result Negative Negative Positive Negative Positive Positive Negative … Negative
Datea 2/3 2/10 2/15 2/17 2/23 2/25 3/3 … 3/4
Patient 5
Type CAS CAS CAS CAS CAS … … … CAS
Result Negative Negative Negative Positive Negative … … … Negative
Datea 5/22 6/2 6/10 6/22 6/28 … … … 7/2
note. See Methods for definitions of clinical active surveillance (CAS) and laboratory-based active surveillance (LAS).
a Date on which swab sample was collected.
mission detected 59% of the patients in our sample who were
colonized with VRE, and an additional 36 patients (12%)
with colonization would have been detected by LAS at some
point during the ICU stay. The percentage of patients from
whom specimens were procured for CAS at admission was
93% (1,734 of 1,872 patients), whereas the percentage at dis-
charge was 53% (984 patients). Forty-one percent of patients
(766) had only one surveillance test performed, and among
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table 5. Estimated Cost Savings of Clinical Active Surveillance (CAS), Compared
With Laboratory-Based Active Surveillance, During a 30-Month Period, According to
Estimated Averted Cases of Vancomycin-Resistant Enterococci (VRE) Colonization and
Associated Bacteremia
Variable
Cost savings associated with
use of CAS, 2003 US$
During 30-mo
study period Per month
Incremental MICU colonization cost savings for levels
of transmission (0.5-2) of undetected VRE










Likelihood of colonized patient becoming bacteremic
Increased cost of VRE bacteremia p $17,143c
7.8% 625,720 20,857
13% 1,032,351 34,412
Increased cost of VRE bacteremia p $36,380d
7.8% 1,327,870 44,262
13% 2,190,804 73,027
note. We assumed a transmission rate of 1.00 (ie, that each case patient with VRE transmitted
VRE to one other person). See Methods for definitions of clinical active surveillance (CAS) and
laboratory-based active surveillance (LAS). MICU, medical intensive care unit.
a From Montecalvo et al.40
b From Puzniak et al.25
c From Carmelli et al.13
d From Stosor et al.8
the patients for whom a discharge surveillance test was not
performed, 381 (43%) of 888 stayed in the ICU for less than
72 hours, and 242 (27%) of 888 died while in the ICU.
Atypical Test Results
Among patients who tested positive for enteric VRE, all but
20 (8%) of 237 patients for whom 2 or more tests were
performed remained VRE positive throughout their ICU stay.
Five patients (0.02%) displayed atypical results of cultures,
with oscillations between negative and positive results for
enteric colonization with VRE (Table 4). Nine patients who
stayed in the ICU for less than 48 hours had an initial culture
that was positive for VRE and a discharge culture that was
negative for VRE. In addition, 6 patients with varying num-
bers of VRE-positive test results had a single surveillance test
that was negative for enteric VRE at ICU discharge.
Programmatic Costs
The total cost estimated for both the CAS and LAS programs
in 2003 dollars was $67,958 for 30 months. The LAS costs
were $10,563, whereas the CAS costs were $57,395. These
estimates include allocated and direct costs, which may vary
among different institutions. Estimated monthly costs for VRE
surveillance were $1,913 for CAS and $352 for LAS (Table
2). The cost was $30.66 per patient for CAS and $5.64 per
patient for LAS. An additional 337 VRE cultures were per-
formed subsequent to a culture that yielded enteric VRE. A
30-month cost savings of $10,367 would have been realized
if VRE surveillance was terminated after a positive test result
was documented. The associated costs of VRE surveillance
would have been $1,568 per month for CAS ($25.12 per
patient) if the cost of these 337 cultures was excluded.
Estimated Cost Savings
The CAS method requires the performance of 4.7 times more
cultures than the LAS method (Table 3). The LAS method
alone would not have identified 234 cases of VRE coloni-
zation, whereas the CAS method identified all but 3 cases of
VRE colonization. Use of CAS would prevent 346.5-693 cases
of VRE colonization, depending on the transmission dynamic
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of VRE, and 36.5-60.22 cases of bacteremia. By applying ex-
cess cost estimates for colonization and bacteremia, adjusted
to 2003 dollars,40 and varying the VRE transmission rate,
prevention of colonization by use of CAS would have an
estimated cost savings ranging from $35,401 to $230,307 per
month, relative to the cost associated with the LAS method
(Table 5).5,21,25 Assuming that 1 case patient with VRE trans-
mits VRE to 1 other person and that, of those colonized with
VRE, between 8% and 13% become VRE bacteremic, the
estimated cost savings attributable to prevented bacteremia
ranges from $20,857 to $73,027 per month.8,13 Taken together,
the total estimated cost savings associated with use of CAS
ranges from $56,258 to $303,334 per month.
discussion
These data suggest that strategic CAS was superior to LAS
for detecting enteric colonization with VRE in an ICU where
VRE is endemic. The excess costs of surveillance were modest
relative to the estimated averted costs of associated infections.
Colonization in most (91%) of the VRE-colonized partici-
pants was initially identified by CAS, a method of surveillance
that routinely surveys the population at risk, prospectively
identifies acquired cases, and allows for the calculation of
colonization pressure.6,38 In contrast, the C. difficile specimen–
associated LAS missed most cases of colonization (76%) in
patients colonized with VRE.31,32,34 We propose that the fo-
cused screening of submitted C. difficile specimens for VRE
may be appropriate for institutions or units within institu-
tions with historically low rates of VRE colonization and
limited resources.43 In such algorithms, if LAS determines an
increase in the prevalence of VRE colonization, then endem-
icity may indicate a need for transition to a CAS method.
Overall, the total costs for the CAS program (estimated to
be $1,913 monthly) were minimal, compared with the esti-
mated averted excess costs attributable to preventing VRE
colonization and bacteremia. The estimated cost savings of
CAS attributable to preventing VRE colonization and bac-
teremia ranged from $56,258 to $303,334 per month. The
large variation resulted from different assumptions about the
VRE transmission rate, the likelihood of a colonized patient
becoming bacteremic, and the increased hospital costs at-
tributable to colonization and bacteremia. Despite the large
variation, all cost-saving estimates greatly exceed the monthly
costs of implementing CAS. Of note, the third-party payer
and societal costs were likely significant and were not ac-
counted for in the resources estimated herein. The additional
benefits of placing patients in isolation to reducing trans-
mission of other transmissible agents, such as extended-spec-
trum b-lactamase–producing bacteria, were not assessed.42
Furthermore, because most VRE-colonized patients remained
colonized with this pathogen, the incremental cost of the CAS
and LAS methods would decrease if subsequent testing did
not occur after the initial positive test result was available,
for an estimated cost savings of $10,367.
We recognize the study limitation associated with decreased
compliance with performing surveillance cultures at ICU dis-
charge (53% of patients), which was low compared with the
percentage of patients (93%) who had cultures performed at
ICU admission; thus, incidence rates for enteric colonization
with VRE were likely to be underestimated. In addition, cost-
to-charge ratios were not calculated because of difficulties
with estimating reimbursements received and because actual
hospital costs are better indicators of economic costs.44 Fi-
nally, placement of a patient in isolation occurred when a
patient was culture positive for VRE, not at admission, lim-
iting an evaluation of direct patient-to-patient transmission.
Colonization pressure for this subset of patients has previ-
ously been used to estimate transmission likelihoods.6 In sum-
mary, we propose that LAS can be used in a prevalence-based
approach to enteric VRE surveillance in low-risk, low-inci-
dence settings, whereas in high-risk settings, such as ICUs
and other units with high colonization pressure for VRE, CAS
surveillance seems most efficient and cost-effective.
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